Core Viewpoint - Tenax Therapeutics Inc (NASDAQ:TENX) is recognized as one of the best-performing micro-cap stocks in 2025, with Guggenheim raising its price target to $25 from $14, citing a unique market position targeting a large, untreated patient population [1][2]. Group 1: Financial and Operational Highlights - Guggenheim has confirmed that Tenax has successfully cleared its financial hurdles and secured enough capital to fund operations through major clinical milestones in 2026, designating it as a "Top Pick for 2026" [2]. - The company conducted a pre-planned statistical review of the first 150 patients in its LEVEL study, confirming that the trial is powered at over 90% to detect the drug's effectiveness, indicating sufficient patient numbers for valid results [3]. - Data variability was lower than initially feared, allowing the company to maintain sufficient statistical power without needing to increase enrollment, with a target of approximately 230 patients [4]. Group 2: Product Pipeline and Focus - Tenax Therapeutics is a specialty pharmaceutical company focused on developing and commercializing therapies for cardiovascular and pulmonary diseases, with key drug candidates including levosimendan for pulmonary hypertension and TNX-201 for angina [5].

Company Overview - Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company focused on developing novel cardiopulmonary therapies using clinical insights [3] - The company owns global rights to develop and commercialize levosimendan, targeting the treatment of PH-HFpEF, the most prevalent form of pulmonary hypertension, for which no product has been approved to date [3] Upcoming Event - Tenax Therapeutics will participate in a fireside chat at the Cantor Global Healthcare Conference 2025, scheduled for September 3-5, 2025, in New York, NY [1] - The presentation will feature Chris Giordano, President & CEO, and Stuart Rich, M.D., Chief Medical Officer, on September 4, 2025, at 10:20 a.m. ET [2] - A live and archived webcast of the presentation will be available on the company's investor relations webpage [2]

Group 1 - Tenax Therapeutics (NASDAQ: TENX) is advancing its drug development plan for levosimendan, currently in phase 3 LEVEL trial [2] - The company is positioned well within the pharmaceutical sector, indicating potential for growth and investment opportunities [2] Group 2 - The Biotech Analysis Central service offers extensive resources for investors, including a library of over 600 biotech articles and a model portfolio of small and mid-cap stocks [2]

Core Insights - Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company focused on developing novel cardiopulmonary therapies [3] - The company will present at the 24th Annual Needham Virtual Healthcare Conference from April 7-10, 2025 [1][2] - Tenax Therapeutics is developing levosimendan for the treatment of PH-HFpEF, the most prevalent form of pulmonary hypertension, for which no product has been approved to date [3] Presentation Details - The corporate presentation will be led by Chris Giordano (President & CEO), Stuart Rich, M.D. (Chief Medical Officer), and Doug Randall (Chief Business Officer) [2] - The presentation is scheduled for April 7, 2025, at 3:45 p.m. ET [2] - A live and archived webcast of the presentation will be available on the company's investor relations webpage [2] Company Overview - Tenax Therapeutics owns global rights to develop and commercialize levosimendan [3] - The company's common stock is listed on The Nasdaq Stock Market LLC under the symbol "TENX" [3]